Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06906250
Recruiting Observational

European Venous Registry

NCT06906250 · tracked via the Priya Life Science Italy tracker
Sponsor
IRCCS San Raffaele
Phase
Observational
Started
2025-07-05
Last updated
2025-09-08

Condition(s) studied

Deep Venous Disease of the Lower Limbs

Study summary

The European Venous Registry (EVeR) is an international repository of data on the treatments and outcomes of people with deep venous disease. The registry is designed to evaluate the outcomes of venous interventions over a ten-year period, with the ultimate goal to inform clinical decision making through the delivery of scientific evidence.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with an imaging-confirmed new diagnosis of acute or chronic lower limb deep venous disease involving the iliac and/or common femoral veins, with or without extension to the inferior vena cava, or patients with an imaging-confirmed new diagnosis involving the IVC only. * Consent to enter registry. Exclusion Criteria: * Unable to consent to enter into registry. * Isolated upper limb DVT. * Central venous thrombosis (e.g. superior vena cava obstruction). * Isolated deep vein thrombosis below the common femoral vein. * Isolated superficial venous thrombosis. * Isolated superficial venous thrombophlebitis. * Isolated varicose veins. * Aged \<18 years.

Primary outcome measure(s)

  • Clinical Severity Scores — end of the procedure
    Difference of Clinical efficacy will be evaluated using the Villalta score (range 0-33). The patient was diagnosed as having Post-thrombotic syndrome if the Villalta score was ≥5 or if a venous ulcer was present. A score of 5-9 signifies mild disease, 10-14 moderate disease, and ≥15 severe disease.

Trial sites (10)

FacilityCityRegionStatus
Department of Vascular Surgery Marseille France Recruiting
European Venous Center Aachen Germany Recruiting
Clinic of Vascular and Endovascular Surgery at Athens Medical Group Athens Greece Recruiting
Interventional Radiology, Galway University Hospitals Galway Ireland Recruiting
IRCCS San Raffaele Hospital Milan Italy Recruiting
Department of Vascular and Endovascular Surgery, Erasmus Medical Centre Rotterdam Netherlands Recruiting
Vascular and Endovascular Department, Viamed Hospitals Madrid Spain Recruiting
Department of Cardiovascular Surgery, Acibadem University School of Medicine, Istanbul Turkey Recruiting
North Bristol NHS Trust Bristol United Kingdom Recruiting
St Thomas' Hospital London United Kingdom Recruiting

More IRCCS San Raffaele trials in Italy

Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen Recruiting
Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma. Recruiting
Medically Assisted Fertilization Techniques in Systemic Immunoreumatologic Diseases Recruiting
Development of Novel Imaging and Molecular Biomarkers of Fibrosis in Patient With Ulcerative Colitis Recruiting
Next-Generation Endometriosis Diagnostics Through Comprehensive Multi-Dimensional Analysis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06906250 on ClinicalTrials.gov ↗ ← All trials in Italy